2023
DOI: 10.1016/j.bioorg.2023.106893
|View full text |Cite
|
Sign up to set email alerts
|

Small molecule tractable PARP inhibitors: Scaffold construction approaches, mechanistic insights and structure activity relationship

Amandeep Thakur,
Mandeep Rana,
Ritika
et al.
Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 174 publications
0
0
0
Order By: Relevance
“…PARP inhibitors are currently the most widely used DDR inhibitors in clinical practice. To date, a large number of PARP inhibitors have been identified 4–6 . Although the success of PARP inhibitors in homologous recombination (HR) deficient ovarian, breast and pancreatic cancers has highlighted the potential of DDR inhibitors, their scope of application remains limited 7–9 .…”
Section: Introductionmentioning
confidence: 99%
“…PARP inhibitors are currently the most widely used DDR inhibitors in clinical practice. To date, a large number of PARP inhibitors have been identified 4–6 . Although the success of PARP inhibitors in homologous recombination (HR) deficient ovarian, breast and pancreatic cancers has highlighted the potential of DDR inhibitors, their scope of application remains limited 7–9 .…”
Section: Introductionmentioning
confidence: 99%